Tirabrutinib

Tirabrutinib (brand name Velexbru) is a drug used for the treatment of autoimmune disorders and hematological malignancies.^[1][2]

Tirabrutinib

Clinical data
Trade names	Velexbru
Other names	GS-4059; ONO-4059
ATC code	L01EL06 (WHO)
Legal status
Legal status	JP: Rx-only
Identifiers
IUPAC name 6-Amino-9-[(3R)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one
CAS Number	1351636-18-4
PubChem CID	54755438
DrugBank	DB15227
ChemSpider	58171734
UNII	LXG44NDL2T
KEGG	D12594
ChEMBL	ChEMBL4071161
PDB ligand	7GB (PDBe, RCSB PDB)
Chemical and physical data
Formula	C25H22N6O3
Molar mass	454.490 g·mol−1

Tirabrutinib was approved in March 2020 in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma.^[1] In addition, tirabrutinib is in clinical development by Ono Pharmaceutical and Gilead Sciences^[3] in the United States, Europe, and Japan for autoimmune disorders, chronic lymphocytic leukemia, B cell lymphoma, Sjogren's syndrome, pemphigus, and rheumatoid arthritis.^[1]

Tirabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase.^[4]